Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 46, 2009, Pages 19274-19279

  Akiyama, Masashi ^a   Takeda, Soichi ^a   Kokame, Koichi ^a   Takagi, Junichi ^b   Miyata, Toshiyuki ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Hemostasis; Metalloproteinase; Modular protein; Substrate recognition

Indexed keywords

DISINTEGRIN; METALLOPROTEINASE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME SUBSTRATE; HEMOSTASIS; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN INTERACTION; PROTEIN STRUCTURE; THROMBOGENESIS; CHEMISTRY; GENETICS; HUMAN; METABOLISM; X RAY CRYSTALLOGRAPHY;

ADAM PROTEINS; CRYSTALLOGRAPHY, X-RAY; HUMANS; PROTEIN INTERACTION DOMAINS AND MOTIFS; VON WILLEBRAND FACTOR;

EID: 72949104661     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0909755106     Document Type: Article

References (44)

1. Porter S, Clark IM, Kevorkian L, Edwards DR (2005) The ADAMTS metalloproteinases. Biochem J 386:15-27.
2. Edwards DR, Handsley MM, Pennington CJ (2009) The ADAM metalloproteinases. Mol Aspects Med 29:258-289.
3. Sadler JE (1998) Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 67:395-424.
4. Ruggeri ZM (2003) Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 1:1335-1342.
5. Sadler JE, Moake JL, Miyata T, George JN (2004) Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program, 407-423.
6. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM (1990) Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA 87:6306-6310.
7. Tsai HM, Sussman II, Nagel RL (1994) Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 83:2171-2179.
8. Moake JL, et al. (1982) Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307:1432-1435.
9. Furlan M, et al. (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339:1578-1584.
10. Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585-1594.
11. Levy GG, et al. (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413:488-494.
12. Soejima K, et al. (2001) A novel human metalloprotease synthesized in the liver and secreted into the blood: Possibly, the von Willebrand factor-cleaving protease? J Biochem 130:475-480.
13. Zheng X, et al. (2001) Structure of von Willebrand factor-cleaving protease (ADAMTS13), ametalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 276:41059-41063.
14. Soejima K, et al. (2003) ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood 102:3232-3237.
15. Zheng X, Nishio K, Majerus EM, Sadler JE (2003) Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem 278:30136-30141.
16. Ai J, Smith P, Wang S, Zhang P, Zheng XL (2005) The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor. J Biol Chem 280:29428-29434.
17. Gao W, Anderson PJ, Sadler JE (2008) Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 contribute to substrate specificity. Blood 112:1713-1719.
18. Klaus C, et al. (2004) Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 103:4514-4519.
19. Luken BM, et al. (2005) The spacer domain of ADAMTS13 contains amajor binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 93:267-274.
20. Gerhardt S, et al. (2007) Crystal structures of human ADAMTS-1 reveal a conserved catalytic domain and a disintegrin-like domain with a fold homologous to cysteine-rich domains. J Mol Biol 373:891-902.
21. Mosyak L, et al. (2008) Crystal structures of the two major aggrecan degrading enzymes, ADAMTS4 and ADAMTS5. Protein Sci 17:16-21.
22. Takeda S (2009) Three-dimensional domain architecture of the ADAM family proteinases. Semin Cell Dev Biol 20:146-152.
23. Tan K, et al. (2002) Crystal structure of the TSP-1 type 1 repeats: A novel layered fold and its biological implication. J Cell Biol 159:373-382.
24. Takeda S, Igarashi T, Mori H, Araki S (2006) Crystal structures of VAP1 reveal ADAMs' MDC domain architecture and its unique C-shaped scaffold. EMBO J 25:2388-2396.
25. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T (2005) FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 129:93-100.
26. Zanardelli S, et al. (2006) ADAMTS13 substrate recognition of von Willebrand factor A2 domain. J Biol Chem 281:1555-1563.
27. de Groot R, Bardhan A, Ramroop N, Lane DA, Crawley JT (2009) Essential role of the disintegrin-like domain in ADAMTS13 function. Blood 113:5609-5616.
28. Zhang Q, et al. (2009) Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor. Proc Natl Acad Sci USA 106:9226-9231.
29. Furlan M, Robles R, Lämmle B (1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87:4223-4234.
30. Tsai HM (1996) Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87:4235-4244.
31. Kokame K, Matsumoto M, Fujimura Y, Miyata T (2004) VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 103:607-612.
32. Luken BM, et al. (2006) Amino acid regions 572-579 and 657-666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP. Thromb Haemost 96:295-301.
33. Gao W, Anderson PJ, Majerus EM, Tuley EA, Sadler JE (2006) Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease. Proc Natl Acad Sci USA 103:19099-19104.
34. Wu JJ, Fujikawa K, McMullen BA, Chung DW (2006) Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor. Proc Natl Acad Sci USA 103:18470-18474.
35. Tortorella M, et al. (2000) The thrombospondin motif of aggrecanase-1 (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage. J Biol Chem 275:25791-25797.
36. Kashiwagi M, et al. (2004) Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing. J Biol Chem 279:10109-10119.
37. Gendron C, et al. (2007) Proteolytic activities of human ADAMTS-5: Comparative studies with ADAMTS-4. J Biol Chem 282:18294-18306.
38. Flannery CR, et al. (2002) Autocatalytic cleavage of ADAMTS-4 (Aggrecanase-1) reveals multiple glycosaminoglycan-binding sites. J Biol Chem 277:42775-42780.
39. Fushimi K, Troeberg L, Nakamura H, Lim NH, Nagase H (2008) Functional differences of the catalytic and non-catalytic domains in human ADAMTS-4 and ADAMTS-5 in aggrecanolytic activity. J Biol Chem 283:6706-6716.
40. Kokame K, et al. (2002) Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 99:11902-11907.
41. Banno F, Miyata T (2008) in Recent Advances in Thrombosis and Hemostasis 2008, eds Tanaka K, Davie EW (Springer, Tokyo), pp 162-176.
42. Akiyama M, Kokame K, Miyata T (2008) ADAMTS13 P475S polymorphism causes a lowered enzymatic activity and urea lability in vitro. J Thromb Haemost 6:1830-1832.
43. Plaimauer B, et al. (2006) Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and amissense mutation. Blood 107:118-125.
44. Akiyama M, Takeda S, Kokame K, Takagi J, Miyata T (2009) Production, crystallization and preliminary crystallographic analysis of exosite-containing fragment of human von Willebrand factor-cleaving proteinase, ADAMTS13. Acta Crystallograph Sect F Struct Biol Cryst Commun F 65:739-742.